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Background: Benzimidazoles and triazoles are useful structures for research and development of new
pharmaceutical molecules and have received much attention in the last decade because of their highly potent
medicinal activities.
Findings: A simple and efficient synthesis of triazole was carried out by treatment of 2-(4-azidophenyl)-1H-benzo[d]
imidazole (6) with different types of terminal alkynes in t-BuOH/H2O, sodium ascorbate, and Zn(OTf)2, screened for
cytotoxicity assay and achieved good results. A series of new benzimidazole-linked 1,2,3-triazole (8a-i) congeners were
synthesized through cyclization of terminal alkynes and azide. These synthesized congeners 8a-i were evaluated for
their cytotoxicity against five human cancer cell lines. These benzimidazole-linked 1,2,3-triazole derivatives have shown
promising activity with IC50 values ranging from 0.1 to 43 μM. Among them, the compounds (8a, 8b, 8c, and 8e)
showed comparable cytotoxicity with adriamycin control drug.
Conclusions: In conclusion, we have developed a simple, convenient, and an efficient convergent approach for the
synthesis of benzimidazole-linked 1,2,3-triazole congeners as agents.
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Cancer is one of the terrible diseases which cause uncon-
trolled growth of group of cells. It remains a mean threat to
human beings and cause death [1,2]. Recently, many re-
searchers developed safe and effective ways of treating this
disease and to search for novel chemotherapeutic agents.
The benzimidazole nucleus is an important pharmacophore
in medicinal chemistry. The synthesis of novel benzimid-
azole derivatives remains a main focus of modern drug dis-
covery. The versatility of new generation benzimidazole
would represent a fruitful pharmacophore for further devel-
opment of better medicinal agents. Many researchers have
been attracted to benzimidazole derivatives because of their
wide range of biological activity. Over the past years, there is
a considerable interest in the development and pharmacol-
ogy of benzimidazole. They are of wide interest because of
their diverse biological activity and clinical applications [3].* Correspondence: elxnkits@yahoo.co.in
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microbial [4,5], antitumor [6], anti-inflammatory [7], anti-
hypertensive [8], and antiviral [9] activities. Benzimidazole
moiety can also be extracted from naturally occurring
compounds such as vitamin B12 and its derivatives, and it is
similar to the structure of purins. Pyrrolo[1,2-a]benzimid-
azoles represent a new class of antitumour agent exhibiting
cytotoxic activity against a variety of cancer cell lines [10].
Benzimidazole containing anticancer agent, [Hoechst-
33342], 2′-(4-ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-
2,5′-bis-1H-benzimidazole (1), has been reported as
inhibitor of topoisomerase-I [11,12]. The other derivative
of benzimidazole [Hoechst-33258] (2 Figure 1) [13,14]
shows both in vitro antitumour activity, as inhibitor of
DNA topoisomerase-I [15]. Hoechst 33258 a fluorescent
reagent and as initially found to be active against L1210
murine leukemia. During phase I trial in humans, some
responses were seen in pancreatic cancer. However, a
subsequent phase II trial did not show any objective
responses.an Open Access article distributed under the terms of the Creative Commons





















Figure 1 Biologically active benzimidazole derivatives.
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http://www.orgmedchemlett.com/content/4/1/14In addition, triazoles also display wide spectrum of
biological activities and are widely employed as
pharmaceuticals and agrochemicals. Triazoles are
reported to possess antibacterial, antifungal, and
antihelminthic activities [16-21]. They have been
regarded as an interesting unit in terms of biological
activity [22,23], and some of them have also shown
significant anticancer activity in many of the human
cell lines [24].
In view of the biological importance of benzimidazole




























Scheme 1 Synthesis 1,2,3-triazoles.benzimidazole and 1,2,3-triazole moieties, it was considered
worthwhile to synthesize certain new chemical entities hav-
ing benzimidazole and 1,2,3-triazole pharmacophores in a
single molecular framework, and here we have used Zn
(OTf)2 catalyst instead of CuSO4. All of these congeners
have been evaluated for their anticancer activity against a
panel of five human cancer cell lines (Figure 1).
Experimental section
All chemicals and reagents were obtained from Aldrich
(Sigma-Aldrich, St. Louis, MO, USA) and Lancaster (Alfa
Aesar, Johnson Matthey Company, Ward Hill, MA, USA)
and were used without further purification. Reactions were
monitored by TLC and performed on silica gel glass plates
containing 60 F-254, and visualization on TLC was achieved
by UV light or iodine indicator. 1H and 13C NMR spectra
were recorded on Gemini Varian-VXR-unity (Palo Alto,
California) (300 and 100 MHz) instrument. Chemical shifts
(d) are reported in ppm downfield from internal TMS
standard. ESI spectra were recorded on Micromass, Quattro
LC (McKinley Scientific, Sparta, NJ, USA) using ESI + soft-
ware with capillary voltage 3.98 kV and ESI mode positive
ion trap detector. Melting points were determined with an
electrothermal melting point apparatus and are uncorrected.
Chemistry
The synthesis of novel benzimidazole linked triazole (8a-i)
derivatives is carried out as shown in Scheme 1. The key
intermediate for the preparation of the new analogs is 2-
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t-BuOH/H2O 1:1, Zn(OTf)2














Table 1 Cytotoxic activity (IC50 μM) of compounds 8a-i
Compound A375 B-16 Colon-205 MCF-7 A-549
8a 2.7 - 1.3 3.2 0.1
8b 2.3 1.9 3.5 1.7 2.6
8c 1.6 16 0.12 1.9 -
8d - 4.7 8 - -
8e 2.1 - 1.3 0.3 1.8
8f 15 3.9 17 - -
8g 43 - 32 - 26
8h - - - 37 32
8i 27 10 21 - -
ADR 0.9 1.0 3.5 3.2 0.03
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was mixed with a sufficient quantity of polyphosphoric
acid. The resulting solution was stirred at 250°C for 4 h,
to afford compound 5. Compound 5 was diazotizated
followed by azidation to afford compound 6. Compound 6
upon treatment with different types of terminal alkynes in
t-BuOH/H2O, sodium ascorbate, and Zn(OTf)2 afforded
compounds (8a-i).
4-(1H-Benzo[d]imidazol-2-yl)benzenamine (5)
A mixture of the O-phenylenediamine (3) (500 mg,
3.64 mmol) and the 4-aminobenzoic acid (4) (394 mg,
3.64 mmol) was dissolved in sufficient quantity of polypho-
sphoric acid (PPA). The mixture was heated slowly to
250°C for 4 h, permitted to cool to room temperature,
quenched with excess of 10% Na2CO3 solution, and ex-
tracted with ethyl acetate. Then, the mixture was dried over
anhydrous Na2SO4, and the crude product was purified by
column chromatography with ethyl acetate/hexane (6:4) to
afford pure compound 5, 946 mg in 97% yield. Mp: 209°C
to 211°C, 1H NMR (300 MHz, DMSO-d6): δ 6.68 (d, 2H,
J =7.3 Hz), 7.14 (br s, 2H), 7.50 (br s, 2H), 7.85 (d, 2H,
J =7.1 Hz). IR (neat, cm−1): γmax 404.3; 501.4; 537.9; 607.7;
742.3; 833.4; 960.1; 1,009.1; 1,108.6; 1,178.6; 1,225.7;
1,272.2; 1,397.2; 1,444.1; 1,499.2; 1,612.4; 1,701.4; 2,750.1;
2,853.1; 2,921.8; 3,355.4; 3,435.0; MS (ESI): 210 [M+H]+.
2-(4-Azidophenyl)-1H-benzo[d]imidazole (6)
The amine derivative (5) (500 mg, 2.39 mmol) was dis-
solved in 10% aq HCl at room temperature. This reaction
mixture upon cooling to 0°C and addition of a solution of
NaNO2 (165 mg, 2.39 mmol) was stirred for 10 min at 0°C
to 5°C. Sodium azide (186 mg, 2.87 mmol) was added, and
the mixture was stirred at room temperature for 2 h. The
reaction was worked up by dilution with ethyl acetate. The
organic layer was washed with brine and dried over
Na2SO4. After evaporation of the solvent, the crude
product was purified by column chromatography with ethyl
acetate/hexane (3:7) to afford pure compound 6, 536 mg in
95% yield; Mp: 317°C to 319°C, 1H NMR (300 MHz,
DMSO-d6): δ 7.16 to 7.26 (m, 2H), 7.32 (d, 2H, J =9.0 Hz),
7.50 to 7.69 (dd, 2H, J =40.0, 38.5 Hz), 8.22 (d, 2H,
J =8.3 Hz), 12.97 (s, 1H). IR (neat, cm−1): γmax 500.6; 541.4;
694.3; 743.3; 838.1; 963.4; 1,011.1; 1,115.8; 1,175.5; 1,283.5;
1,395.2; 1,438.8; 1,485.1; 1,604.6; 1,726.8; 2,120.1; 2,414.9;
2,856.9; 2,918.2; 3,055.5; 3,422.9; MS (ESI): 236 [M+H]+.
2-(4-(4-(3,4,5-Trimethoxyphenyl)-1H-1,2,3-triazol-1-yl)
phenyl)-1H-benzo[d]imidazole (8a)
Amixture of the corresponding azide 6 (200 mg, 0.85 mmol)
and the corresponding alkyne 7a (163 mg, 0.85 mmol) was
dissolved in t-BuOH/H2O 1:1 (20 mL). Sodium ascorbate
(33 mg, 20 mol%) and Zn(OTf)2 (300 mg, 5 mol%) were
added. After stirring for 4 h, water/ice (40 mL) was added.The product was either worked up by filtration, followed by
rinsing with aqueous 5% NH3 (×3) and cold ether (×2), or
by extraction with dichloromethane (4 × 100 mL). The com-
bined organic layers were washed with aqueous 5% NH3
(3 × 100 mL) and brine (100 mL) and dried over anhydrous
MgSO4. The solvent was removed in vacuo, and the crude
product was purified by column chromatography with ethyl
acetate/hexane (3:7) to afford pure compound 8a, 347 mg in
95% yield. Mp: 270°C to 272°C, 1H NMR (400 MHz,
CDCl3): δ 3.71 (s, 3H), 3.89 (s, 6H), 7.24 to 7.28 (m, 4H),
7.63 to 7.66 (m, 2H), 8.17 (d, 2H, J =8.4 Hz), 8.41 (d, 2H,
J =8.4 Hz), 9.44 (s, 1H). 13C NMR (100 MHz, CDCl3): δ
57.2, 61.4, 110.2, 114.8, 117.1, 122.1, 123.3, 125.3, 128.4,
129.8, 140.1, 141.8, 143.3, 148.7, 152.4, 154.1; MS (ESI): 428
[M+H]+.
The other derivatives are also prepared according to
the same procedure and described in Additional file 1.
Biological evaluation
In vitro cytotoxicity assay
The synthesized compounds 8a-i were evaluated for their
anticancer activity in selected human cancer cell lines of
A375, B-16, colon-205, MCF-7, and A-549 by using MTT
assay. All the compounds (8a-i) exhibited significant anti-
cancer activity with IC50 values ranging from 0.1 to
43 μM, while the positive control, adriamycin, demon-
strated the IC50 in the range of 0.03 to 3.5 μM respect-
ively, in the cell lines employed as shown in Table 1.
Procedure for MTT assay
Toxicity of test compound in cells was determined by
MTT assay based on mitochondrial reduction of yellow
MTT tetrazolium dye to a highly colored blue formazan
product. Cells (1 × 104) (counted by Trypan blue exclu-
sion dye method) in 96-well plates were incubated with
compounds with series of concentrations tested for 48 h
at 37°C in RPMI/DMEM/MEM with 10% FBS medium.
Then, the above media was replaced with 90 μl of fresh
serum free media and 10 μl of MTT reagent (5 mg/ml),
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above media was replaced with 200 μl of DMSO and in-
cubated at 37°C for 10 min. The absorbance at 570 nm
was measured on a spectrophotometer (SpectraMax,
Molecular devices, Sunnyvale, CA, USA). IC50 values
were determined from plot: percent inhibition (from
control) versus concentration.Additional file
Additional file 1: Experimental procedure and characterization data
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